Download PDF Introduction The healthcare industry saw a surge in M&A activity post-pandemic in 2021 which stretched across geographies and was driven by an incentive to consolidate healthcare systems to exploit economies of scale, fill pipelines, and boost top-line growth. In 2022, macroeconomic conditions, namely uncertainty, inflation, and high labour Read more…
Download PDF Introduction Facing rising scrutiny from American activist investors, GlaxoSmithKline (GSK), Britain’s second-largest pharmaceutical company, is undertaking a major strategic shift. By spinning off its consumer healthcare division, and recently acquiring Sierra Oncology for $1.9bn, which is about to introduce a new blood cancer treatment to the market, GSK Read more…
Download PDF Merck & Co. (NYSE: MRK) Market Cap as of 8th October 2021 – $204.10bn Acceleron Pharma, Inc. (NASDAQ: XLRN) Market Cap as of 8th October 2021 – $10.68bn Introduction On Thursday 30th September, Merck & Co.’s acquisition of Acceleron Pharma for a total consideration of about $11.5bn was announced. Merck has agreed Read more…
Download PDF Introduction The pharmaceuticals sector has been the center of attention lately for the successful vaccines trial that finally gave some hope of recovery, even though it wasn’t without controversies. However, a lot more has been going on in the industry that might change the reputation that the industry Read more…
Novartis AG (SIX: NOVN) – market cap as of 20/04/2018: CHF204.12bn AveXis Inc (NASDAQ: AVXS) – market cap as of 20/04/2018: $7.62bn Introduction On April 9, Novartis submitted an offer to acquire all the shares of the American gene therapy group AveXis. The Swiss drugmaker offered an 88% premium adding Read more…
Introduction In January 2018, M&A activity surpassed investors’ expectations. According to a report by law firm Baker McKenzie, global mergers and acquisitions are expected to hit an 18-year record, reaching $3.2 trillion in 2018. To the same extent, cross-border M&A is expected to reach new time highs. In the December Read more…
Novartis AG (NYSE:NVS) – market cap as of 04/11/2017: $219bn Advanced Accelerator Applications SA (NASDAQ:AAAP) – market cap as of 04/11/2017: $3.56bn Introduction On October 30, 2017, Novartis announced its intention to make a tender offer for 100% of the share capital of Advanced Accelerator Applications, for a total consideration Read more…
Impax Laboratories, Inc. (IPXL:NASDAQ) – market cap as of 27/10/2017: $1.40bn Introduction On October 17, 2017, Amneal Pharmaceuticals and Impax Laboratories announced that they will merge in an all-stock transaction. Amneal will hold c. 75% of the combined entity, whereas Impax shareholders will own the remaining stake (c. 25%). These Read more…
Kite Pharma (NASDAQ:KITE) – Market cap as of 23/09/2017: $10.28bn Gilead Sciences (NASDAQ:GILD) – Market cap as of 23/09/2017: $108.74bn Introduction On August 28, 2017, Gilead Sciences, Inc. and Kite Pharma, Inc. announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for Read more…
Stada Arzneimittel AG (FWB: SAZ) – market cap as of 21/04/2017: €4.02bn Intel Cinven Partners LLP – private company – AUM as of FY 2015: €10.60bn Bain Capital Private Equity, LP – private company – AUM as of 04/04/2017: $32.40bn Introduction On April 10, 2017, Bain Capital Private Equity, LP Read more…
Allergan PLC (NYSE: AGN) – market cap as of 16/02/2017: $82.86bn Zeltiq Aesthetics Inc. (NASDAQ: ZLTQ) – market cap as of 16/02/2017: $2.23bn Introduction On February 13, 2017, the biopharmaceutical giant Allergan PLC announced that it entered into an agreement to purchase the medical technology company Zeltiq Aesthetics Inc. in Read more…
Johnson & Johnson (NYSE: JNJ) — market cap as of 10/02/2017: $310.36bn Actelion (VTX: ATLN) – market cap as of 10/02/2017: CHF 28.13bn Introduction On the January 26, 2017, the US healthcare behemoth Johnson & Johnson announced the acquisition of the Swiss biotech company Actelion for $30bn in cash. Read more…
Mylan N.V.; market cap as of 12/02/2016: $20.54bn Meda AB; market cap as of 12/02/2016: kr52.44bn ($6.24bn) Introduction On February 10, Mylan NV (NASDAQ: MYL.O) announced its acquisition of Meda AB (STO: MEDAa.ST) in a deal worth $7.2bn made of cash and stock, while the latter reported an unexpected slowdown Read more…
Pfizer Inc.; market cap as of 27/11/2015: $202.7bn Allergan plc; market cap as of 27/11/2015: $126bn Introduction On November 23, 2015, Pfizer Inc. (NYSE: PFE) and Allergan plc (NYSE: AGN) announced that their boards of directors have unanimously approved a definitive merger agreement under which Pfizer will combine with Read more…
Valeant Pharmaceuticals; Market Cap: $25.73bn (as of 13/11/2015) Introduction Valeant Pharmaceutical, a pharma behemoth renowned for its aggressive acquisition strategy, has been facing some hard times as its stellar performance has deteriorated considerably amid scrutiny over its monopoly pricing for its drugs as well as recent accusations for its Read more…